Farhad Mazdisnian, MD
NPI 1750469201 · Pulmonary Disease Physician · Duarte, CA
Enrolled with Medicare as Practitioner - Pulmonary Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1750469201
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Male
- Sole proprietor
- No
- License
- A64550 (CA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,086 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With High Level of Medical Decision Making, If Using Time, 40 Minutes Or More99215 | 243 | $153 |
| Visit Complexity Inherent to Evaluation and Management Associated With Medical Care Services That Serve As the Continuing Focal Point for All Needed Health Care Services And/Or With Medical Care Services That Are Part of Ongoing Care Related to a Patient'SG2211 | 124 | $18 |
| Critical Care, First 30-74 Minutes99291 | 111 | $224 |
| Test to Examine How Well the Lungs Exchange Gases94729 | 64 | $9 |
| Test to Determine Lung Volumes Using Gas Dilution Or Washout94727 | 58 | $13 |
| Initial Hospital Care With Moderate Level of Medical Decision Making, If Using Time, at Least 75 Minutes |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 13 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 99 | 33 |
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 50 | 16 |
| Fluticasone/Vilanterolbrand: Breo Ellipta | 35 | — |
| Fluticasone Propion/Salmeterolbrand: Wixela Inhub | 32 | — |
| Umeclidinium Brm/Vilanterol Trbrand: Anoro Ellipta | 31 | — |
| Prednisone | 31 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$2,229 across 10 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-11-01
- Last updated
- 2022-04-20
- Certified
- 2022-04-20
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.